Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors

Sandström Gerdtsson, Anna LU ; de Matos Rodrigues, Joana LU ; Eskelund, Christian Winther ; Husby, Simon ; Gronbaek, Kirsten ; Räty, Riikka ; Kolstad, Arne ; Geisler, Christian H. ; Porwit, Anna LU and Jerkeman, Mats LU , et al. (2023) In Haematologica 108(4). p.1092-1104
Abstract
The variable outcome to standard immunochemotherapy for mantle cell lymphoma (MCL) patients is a clinical challenge. Established risk factors, including high MCL international prognostic index (MIPI), high proliferation (Ki-67), non-classic (blastoid/pleomorphic) morphology, and mutated TP53, only partly identify patients in need of alternative treatment. Deepened understanding of biological factors that influence time to progression and relapse would allow for an improved stratification, and identification of novel targets for high-risk patients. We performed gene expression analyses to identify pathways and genes associated with outcome in a cohort of homogeneously treated patients. In addition to deregulated proliferation, we show that... (More)
The variable outcome to standard immunochemotherapy for mantle cell lymphoma (MCL) patients is a clinical challenge. Established risk factors, including high MCL international prognostic index (MIPI), high proliferation (Ki-67), non-classic (blastoid/pleomorphic) morphology, and mutated TP53, only partly identify patients in need of alternative treatment. Deepened understanding of biological factors that influence time to progression and relapse would allow for an improved stratification, and identification of novel targets for high-risk patients. We performed gene expression analyses to identify pathways and genes associated with outcome in a cohort of homogeneously treated patients. In addition to deregulated proliferation, we show that thermogenesis, fatty acid degradation and oxidative phosphorylation are altered in patients with poor survival, and that high expression of carnitine palmitoyltransferase 1A (CPT1A), an enzyme involved in fatty acid degradation, can specifically identify high-risk patients independent of the established high-risk factors. We suggest that complementary investigations of metabolism may increase the accuracy of patient stratification and that immunohistochemistry-based assessment of CPT1A can contribute to defining high-risk MCL. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Haematologica
volume
108
issue
4
pages
1092 - 1104
publisher
Ferrata Storti Foundation
external identifiers
  • pmid:36519324
  • scopus:85151538169
ISSN
0390-6078
DOI
10.3324/haematol.2022.281420
language
English
LU publication?
yes
id
30b38a16-85a1-443a-bc1b-d97923c4417a
date added to LUP
2023-02-24 09:46:23
date last changed
2023-05-22 12:33:34
@article{30b38a16-85a1-443a-bc1b-d97923c4417a,
  abstract     = {{The variable outcome to standard immunochemotherapy for mantle cell lymphoma (MCL) patients is a clinical challenge. Established risk factors, including high MCL international prognostic index (MIPI), high proliferation (Ki-67), non-classic (blastoid/pleomorphic) morphology, and mutated TP53, only partly identify patients in need of alternative treatment. Deepened understanding of biological factors that influence time to progression and relapse would allow for an improved stratification, and identification of novel targets for high-risk patients. We performed gene expression analyses to identify pathways and genes associated with outcome in a cohort of homogeneously treated patients. In addition to deregulated proliferation, we show that thermogenesis, fatty acid degradation and oxidative phosphorylation are altered in patients with poor survival, and that high expression of carnitine palmitoyltransferase 1A (CPT1A), an enzyme involved in fatty acid degradation, can specifically identify high-risk patients independent of the established high-risk factors. We suggest that complementary investigations of metabolism may increase the accuracy of patient stratification and that immunohistochemistry-based assessment of CPT1A can contribute to defining high-risk MCL.}},
  author       = {{Sandström Gerdtsson, Anna and de Matos Rodrigues, Joana and Eskelund, Christian Winther and Husby, Simon and Gronbaek, Kirsten and Räty, Riikka and Kolstad, Arne and Geisler, Christian H. and Porwit, Anna and Jerkeman, Mats and Ek, Sara}},
  issn         = {{0390-6078}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{1092--1104}},
  publisher    = {{Ferrata Storti Foundation}},
  series       = {{Haematologica}},
  title        = {{Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors}},
  url          = {{http://dx.doi.org/10.3324/haematol.2022.281420}},
  doi          = {{10.3324/haematol.2022.281420}},
  volume       = {{108}},
  year         = {{2023}},
}